Att'y Dkt. No. 033-004 U.S. App. No. 10/561,902



In re Application of:	
SCHÜLE et al.	Art Unit: [to be assigned]
Appl. No.: 10/561,902	Examiner: [to be assigned]
Filing Date: December 21, 2005	Atty. Docket: 033-004
Title: MODULATION OF OSTEOBLAST ACTIVITY OF FHL2	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on the accompanying Form PTO-1449 and/or List of Potentially Related Patent Applications are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

⊠1.	This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.						
□ 2.	AND	after the	ion Disclosure Statement is being filed more than three months after the U.S. filing date e mailing date of the first Office Action on the merits, but before the mailing date of a Final Notice of Allowance.				
		a. b. 37 C. c.	Below is a certification under 37 C.F.R. § 1.97(e). Attached is my check no in the amount of \$ in payment of the fee under F.R. § 1.17(p). Please charge my Deposit Account No. <u>50-2821</u> in the amount of \$ for the fee under 37 C.F.R. § 1.17(p)				

Att'y Dkt. No. 033-004 U.S. App. No. 10/561,902

□ 3.	This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant hereby Petitions that the Information Disclosure Statement be considered. Attached is my check please charge my Deposit Account No. 50-2821 in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).					
<u> </u>	Certification(s) under 37 C.F.R. § 1.97(e):					
	a.	I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).				
	□ b.	I hereby certify that no item of information on this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).				
		he non-English language document(s) is discussed in the present specification. See pages pecification of the present application.				
⊠ 6.	The document(s) was/were cited in a corresponding foreign application; \boxtimes a copy of a search report issued in the foreign application is attached, and/or \square an English language version of the foreign search report is attached for the Examiner's information. M.P.E.P. § 609 III (A)(3).					
7 .	A concise explanation of the relevance or a direct translation of the non-English language document(s) is attached hereto or appears below.					
8.	One or more of the items of information on this Information Disclosure Statement constitute a related patent application. It has been determined by viewing Private PAIRS that these related patent applications are available to the Examiner through the USPTO's Image File Wrapper System (IFW), and therefore, a copy or copies of the specification, including claims, and drawings have not been provided, in accordance with the "Waiver of the Copy Requirement in 37 C.F.R. §1.98 for Cited pending U.S. Patent Applications" issued September 21, 2004. If the related patent applications are not available via the IFW, a copy or copies are provided herewith. If these applications are published, the citation is to the Publication Number. The identification of this (these) U.S. Patent Application(s) is not to be construed as a waiver of secrecy as to that application(s) now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.					
□ 9.	, which is relie	documents were cited by or submitted to the Office in Application No, filed dupon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents d. 37 C.F.R. § 1.98(d).				

Att'y Dkt. No. 033-004 U.S. App. No. 10/561,902

□ 10.	Copies of the documents cited in the International Search Report (PCT/ISA/210) and/or the International Preliminary Examination Report (PCT/IPEA/416) have been received by the U.S. P.T.O., as indicated on the Notification of Acceptance (PCT/DO/EO/903); accordingly, additional copies are not provided herewith. M.P.E.P. §§ 609 II, 1892.03(g).					
⊠ 11.	Copies of the U.S. patent documents cited on the PTO-1449 filed herewith are NOT provided, in accordance with <u>Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003</u> , 1276 Off. Gaz. Pat. Office 55 (August 5, 2003).					
<u> </u>	2. Other:					
	It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449 and/or					
List of Potentially Related Patent Applications, and to indicate in the official file wrapper of this patent						
applica	tion that the documents have been considered.					
	Respectfully submitted,					
	By: Shelly Guest Cermak Reg. No. 39,571					

Date: January 9, 2006

U.S. P.T.O. Customer Number 36844

~ Cermak & Kenealy, LLP 515 E. Braddock Road, Suite B Alexandria, VA 22314 703.778.6608

INSOLUCION DISCLOSI DE STATEMENT APPLICANT(S): SCHÜLE et al. FILLIO DATE: Document Publish NAME CLASS SUB-CLASS FILING DATE NUMBER NUMBER DOCUMENT NUMBER DOCUMENT NUMBER DOCUMENT NUMBER DOCUMENT NUMBER DOCUMENT DATE COUNTRY CLASS SUB-CLASS FILING DATE NUMBER NUMBER FOREIGN PATENT DOCUMENTS EXAMINER FOREIGN PATENT DOCUMENTS CLASS SUB-CLASS FILING DATE NUMBER FOREIGN PATENT DOCUMENTS REMAINER FOREIGN PATENT DOCUMENTS CLASS SUB-CLASS TRANSLATION NUMBER NUMBER ON	FORM PTO 1449				ATTY. DKT. NO.:	- 1	APP. NO.:	
SCHÜLE et al. FILING DATE: DOCUMENT NUMBER DATE 6,333,312 12/25/01 Kuberasampath et al. FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS EXAMINER NUMBER DATE FOREIGN PATENT DOCUMENTS EXAMINER NUMBER DATE FOREIGN PATENT DOCUMENTS EXAMINER NUMBER DOCUMENT NO NO NO NO OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein FIFL2 NO NO OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein FIFL2 No No OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein FIFL2 No No OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein FIFL2 No No OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) No OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) No OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) No Date of the Vertice of the Ve				r	033-004		10/561,902	
FILING DATE: December 21, 2005 EXAMINER DOCUMENT NUMBER DATE 6,333,312 12/25/01 Kuberasampath et al. EXAMINER DOCUMENT NUMBER FOREIGN PATENT DOCUMENTS EXAMINER DOCUMENT NUMBER EXAMINER DOCUMENT DATE EXAMINER DOCUMENT NUMBER EXAMINER DOCUMENT DATE EXAMINER DOCUMENT EXAMINER DATE EXAMINER	INFOR	MATION DISCLOSURE	STATEMEN	<u>,</u>				
EXAMINER NITIAL DOCUMENT PUB'N NAME CLASS SUB-CLASS FILING DATE 6,333,312 12/25/01 Kuberasampath et al. FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS EXAMINER DOCUMENT DATE EXAMINER DOCUMENT DATE EXAMINER NUMBER DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION NITIAL WO99/S1727 10/14/99 WO EYes NO NO Yes NO NO Yes NO Yes NO OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)". J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai, C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleels of RVINX2/CBFA I Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.		- 1	a soul	1		<u>-</u>	Consum And I India	
EXAMINER NITIAL DOCUMENT PUB'N NAME CLASS SUB-CLASS FILING DATE 6,333,312 12/25/01 Kuberasampath et al. FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS EXAMINER DOCUMENT DATE EXAMINER DOCUMENT DATE EXAMINER NUMBER DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATION NITIAL WO99/S1727 10/14/99 WO EYes NO NO Yes NO NO Yes NO Yes NO OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)". J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai, C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleels of RVINX2/CBFA I Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.			AN OB TOWN &	3)				
EXAMINE NITIAL ACCOUNTENT DATE DATE COUNTRY CLASS SUB-CLASS FILING DATE		\ <u>\</u>		/	December 21, 2003		TO be Assigned	
EXAMINE NITIAL ACCOUNTENT DATE DATE COUNTRY CLASS SUB-CLASS FILING DATE		(A)	To - MERCE []	IS F	PATENT DOCUMENT	S		
NUMBER 6,333,312 12/25/01 Kuberasampath et al. 6,333,312 12/25/01 Kuberasampath et al. FOREIGN PATENT DOCUMENTS EXAMINER INTIAL WO99/51727 10/14/99 WO 12/45 WO99/51727 10/14/99 WO 12/45 No	EYAMINED	DOCUMENT	PUR'N	T			SUB-CLASS	FILING DATE
FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS EXAMINER NUMBER WO99/51727 I0/14/99 WO BYes No Yes No OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein S (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)." J. Biol. Chem. 2002;17(4):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human hear," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Grow and a half LIM protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai, C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.					14711412	CEAGO	JOB CERTOS	TIBING BITTE
FOREIGN PATENT DOCUMENTS EXAMINER NUMBER WO99/51727 I0/14/99 WO SYes No No No No No No No No No N				Κι	berasampath et al.	- 		
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION NUMBER WO99/51727 10/14/99 WO Elyes No No Pyes Pye					F			
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION NUMBER WO99/51727 10/14/99 WO Elyes No No Pyes Pye					· · · · · · ·			
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION NUMBER WO99/51727 10/14/99 WO Elyes No No Pyes Pye								
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION NUMBER WO99/51727 10/14/99 WO Elyes No No Pyes Pye								
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION NUMBER WO99/51727 10/14/99 WO Elyes No No Pyes Pye	-							
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION NUMBER WO99/51727 10/14/99 WO Elyes No No Pyes Pye								
DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION NUMBER WO99/51727 10/14/99 WO Elyes No No Pyes Pye								
NUMBER WO99/51727 10/14/99 WO EYes No No No Yes No No Yes No No No Yes No Yes No No Yes Yes Yes No Yes Yes Yes Yes Yes Yes No Yes Y			FOR	EIG	N PATENT DOCUME	NTS		
No Yes		l .	DATE		COUNTRY	CLASS	SUB-CLASS	TRANSLATION
□ Yes □ No □ Yes □ Yes □ No □ Yes		WO99/51727	10/14/99	W	0	·		
No Yes No				—				
□ Yes □ No □ Yes □ Yes □ No □ Yes □			1					
□ No □ Yes □ No □ Ye				_				
□ Yes □ No OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)," J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.								
OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)," J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.			+	+				
OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)," J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.								
OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)," J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.			1					
OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)," J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.								
OTHER (Including Author, Title, Date, Pertinent Pages, Publisher, etc.) Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)," J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.								□Yes
 Amaar, Y. G., et al., "Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)," J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798. 								□ No
Protein 2 (FHL2)," J. Biol. Chem. 2002;277(14):12053-12060. Chan, K. K., et al., "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.								
expressed in human heart," Gene 1998;210:345-350. Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.						(IGFBP-5)	Interacts with a Fo	our and a Half LIM
Johannessen, M., et al., "Activation of the coactivator four-and-a-half-LIM-only protein FHL2 and the c-fos promoter through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.						L2, a novel L	.IM domain protei	n preferentially
through inhibition of protein phosphatase 2A," Biochem. Pharmacol. 2003;65:1317-1328. Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.								
 Kong, Y., et al., "Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to β-Adrenergic Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798. 								d the c-fos promoter
Stimulation," Circulation 2001;103(22):2731-2738. Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.								
Lai., C. F., et al., "Four and a half LIM protein 2 (FHL2) stimulates osteoblast proliferation and differentiation," J. Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.						e Hypertroph	ic Response to β-	Adrenergic
Bone Mineral Res. 2002;17(1):S129. Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.							analifonation and d	iffconnection 22 T
Müller, J. M., et al., "The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus," The EMBO Journal 2002;21(4):736-748. Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.				ı pro	tem 2 (FHL2) stimulate	es osteodiast [profiferation and d	interentiation, J.
Vaughan, T., et al., "Alleles of RUNX2/CBFA1 Gene Are Associated With Differences in Bone Mineral Density and Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.		Müller, J. M., et al., "T	he transcription			its Rho signa	ls from the cell me	embrane into the
Risk of Fracture," J. Bone Mineral Res. 2002;17(8):1527-1534. Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.								
Copy of International Search Report for PCT App. No. PCT/EP2004/006798 (30 September 2004). Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.						ited With Dif	terences in Bone l	Mineral Density and
Copy of Written Opinion for PCT App. No. PCT/EP2004/006798.						04/00/700 /	20.0	4)
							so September 2004	+).
		1 Copy of written Opinio	m for PCT App). INC	. FC1/EP2004/000/98.	•		
						•		

	_
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through	
citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	